Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV005 vaccine efficacy against DENV-2 challenge in healthy adults
NCT02317900Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing TV005 Group with Placebo Group (2 arms). Primary endpoints: Frequency of viremia in participants administered rDEN2∆30-7169 and Proportion of participants developing rash and/or neutropenia following rDEN2∆30-7169. Started Dec 2014; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02317900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317900.